Navigation Links
HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
Date:7/28/2010

SEATTLE, July 28 /PRNewswire/ -- HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M. The financing is intended to help advance HemaQuest's two lead products, HQK-1001 and HQK-1004, through Phase 2b clinical trials. Latterell Venture Partners joins the HemaQuest investor syndicate which includes Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. In conjunction with the financing, James Woody, MD, PhD, General Partner at Latterell Venture Partners, has joined HemaQuest's Board of Directors.

"HemaQuest is focusing on much needed clinical therapies for serious and life threatening orphan diseases. As a clinician who has cared for such patients, it is clear the unmet need is large and there is a significant need for novel new medications," said Dr. Woody. "The company, with excellent leadership and considerable skill in the hematology and oncology space, has made great progress with the two lead compounds, with promising results in early clinical trials. We look forward to working closely with our colleagues at HemaQuest to advance these important drugs into registration trials, and eventually to patients."

Fred Dotzler, Managing Director of De Novo Ventures and HemaQuest's Chairman of the Board, said, "The investment by Latterell Venture Partners provides further validation to the Company's technologies and progress in developing programs for its two lead products.  We are delighted to have the very talented Jim Woody join the Board of Directors."

ABOUT HEMAQUEST PHARMACEUTICALS

HemaQuest Pharmaceuticals (www.HemaQuest.com) is a Seattle-based biopharmaceutical company focused on developing small molecule therapeutics based on its proprietary short chain fatty acid technologies to treat orphan hematologic diseases. HQK-1001 is an orally administered small molecule therapeutic being developed to treat the two most common hemoglobin disorders, sickle cell disease and beta thalassemia. The drug candidate has advanced through Phase 1 clinical trials and is completing testing in proof of concept clinical studies in patients with sickle cell disease and beta thalassemia. HQK-1004 is a unique therapy designed to treat malignancies associated with Epstein-Barr virus. A Phase 2 clinical trial is being initiated with this drug candidate.

CONTACT:  Jerome Lyons, Office Manager   T: 206.826.9900   jlyons@hemaquest.com


'/>"/>
SOURCE HemaQuest Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
2. Foundation Venture Capital Group Sells Interest in Longevica Pharmaceuticals
3. Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
4. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
5. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
6. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
7. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
8. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
9. Lotus Pharmaceuticals Terminates SEDA
10. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
11. China Yongxin Pharmaceuticals Inc. Announces the Expansion of Its Chain of Retail Stores to 110 Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017 A recent research report published by ... alone is expected to reach a value of $55.8 billion by ... with 28 states have legalized marijuana for medical uses. In 2016, ... , North Dakota , Ohio ... use the drug in medical applications such as chemotherapies and pain ...
(Date:2/27/2017)... , Feb 27, 2017 Period October – December 2016 ... Operating result amounted to SEK -16.4 (-6.4) million Result ... share (-0.22) before and after dilution Cash flow from operating ... ... SEK 0.4 (0.4) million Operating result amounted to SEK -39.5 ...
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... ... not your typical author. She went from working as a movie extra on Bill Murray’s ... she isn’t swimming as a performing mermaid. , Her book isn’t typical either. In Carothers’ ... comedic look at the dysfunctions of God’s family, before Lucifer was sent to hell. ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed ... that despite scientific studies, the Center for Disease Control ( CDC ) and Infectious ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... clinic serving San Francisco and environs, is proud to announce an upgrade to ... information on the upgraded Yelp page on topics as diverse as Platelet Rich ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... and reporting for healthcare organizations. This comprehensive and customizable solution empowers StaffBridge ... StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting data, ...
Breaking Medicine News(10 mins):